Evidence map›Paper›PMID 38136389›Full record

ArticleCancers2023

Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.

Paul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, Prih Rohra, Keyi Zhu, F Anthony San Lucas, Eric Konnick, Patrick G Pilie, Bilal Siddiqui, Christopher J Logothetis and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Paul V ViscuseDepartment of Medicine, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0003-0834-8688
Rebecca S Slack-TidwellDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-3041-8582
Miao ZhangDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Prih RohraDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Keyi ZhuDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
F Anthony San LucasDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Eric KonnickDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-5904-1788
Patrick G PilieDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bilal SiddiquiDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6806-1294
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Paul CornDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Rama SoundararajanDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ana AparicioDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Washington · USUniversity of Virginia · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aggressive-variant prostate cancerimmunohistochemistrymolecular biomarkernext-generation sequencing

Identifiers

PMID38136389
PMCPMC10741546
OpenAlexW4389794482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.